News & Perspective

Feb 23, 2009

Feb 23, 2009

Researchers find antibody that fights H5N1, seasonal flu strains

(CIDRAP News) – In a development that could create new tools to prevent and treat seasonal and pandemic influenza, researchers have identified and tested human monoclonal antibodies (mAbs) that can neutralize influenza A viruses, including lethal H5N1 avian influenza.

Oct 29, 2008

Oct 29, 2008

Experts at HHS webinar cite key pandemic planning issues

(CIDRAP News) – The US Department of Health and Human Services (HHS) today hosted an online conversation among experts, government officials, and members of the public that touched on emerging issues in pandemic planning, such as anticipating supply chain interruptions and keeping the momentum going during tough economic times.

Jan 18, 2008

Jan 18, 2008

ACLU sees coercive theme in federal pandemic plans

(CIDRAP News) – The American Civil Liberties Union (ACLU) this week charged that federal pandemic planning efforts rely too heavily on law enforcement and national security approaches, in effect making people, not disease, the enemy.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Nov 02, 2007

Nov 02, 2007

THE PANDEMIC VACCINE PUZZLE Part 7: Time for a vaccine 'Manhattan Project'?

Editor's note: This is the last in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time.

Oct 26, 2007

Oct 26, 2007

THE PANDEMIC VACCINE PUZZLE Part 2: Vaccine production capacity falls far short

Editor's note: This is the second in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame.

Jul 16, 2007

Jul 16, 2007

Study: Inhibiting cytokine response might not reverse H5N1 infections

(CIDRAP News) – Scientists have hoped that disabling the body's destructive immune-system overreaction to the H5N1 avian influenza virus, known as "cytokine storm," could lead to new lifesaving treatments, but according to a new study, trials testing the strategy didn't protect mice infected with the disease.

Feb 08, 2007

Feb 08, 2007

2007 SUMMIT COVERAGE: Notable quotes from business summit on pandemic issues

(CIDRAP News) – Predictions and observations at this week's conference on business preparedness for pandemic influenza ran the gamut from how fast a pandemic would circle the globe to how well the Internet would hold up, with many topics in between.

Feb 06, 2007

Feb 06, 2007

2007 SUMMIT COVERAGE: CDC chief calls pandemic preparedness a marathon

(CIDRAP News) – Orlando, FL – Julie Gerberding, MD, director of the Centers for Disease Control and Prevention (CDC), today challenged health and business leaders to stay focused on the "marathon" of preparing for an influenza pandemic.

Gerberding, speaking at a conference on business preparedness, said it's not possible to maintain high public interest in the pandemic threat indefinitely, but leaders must keep preparing anyway.

Pages

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»